Skip to main content
. 2021 Aug 13;13:745–755. doi: 10.2147/CEOR.S317078

Table 3.

Results of the Cost-Effectiveness Analysis

LY QALY Costs Difference, Apixaban vs Comparator ICER (€/QALY)
Total Monitoring Event Drug Cost LY QALY
Apixaban 8.37 6.09 18,342 1068 13,356 3918
Rivaroxaban 8.32 6.05 18,385 1057 13,703 3625 −43 0.05 0.03 Apixaban dominates
Dabigatran 8.23 5.98 18,746 1046 14,588 3112 −404 0.13 0.11 Apixaban dominates
Warfarin 8.22 5.94 22,033 5877 16,008 149 −3691 0.15 0.14 Apixaban dominates